All In Biotech

NDA 217684 · Pyros Pharms

Vigafyde

Vigabatrin · Oral · Anti-epileptic Agent

Orphan

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jun 17, 2024

Approved uses

2

Original approval plus efficacy supplements

Registered trials

28

6 Phase 3, 2 recruiting

FAERS reports

4,764

3,805 serious, 453 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: PERMANENT VISION LOSS VIGAFYDE can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, VIGAFYDE also can damage the central retina and may decrease visual acuity [see Warnings and Precautions ( 5.1 )]. The onset of vision loss from VIGAFYDE is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years. Symptoms of vision loss from VIGAFYDE are unlikely to be recognized by patients or caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function. The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss. Vision assessment...

What it is approved for

From the label in effect Nov 1, 2025.

VIGAFYDE is indicated as monotherapy for the treatment of i nfantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss. ( 1 ) VIGAFYDE is indicated as monotherapy for the treatment of infantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [see Warnings and Precautions ( 5.1 )].

Mechanism: The precise mechanism of vigabatrin’s anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system. No direct correlation between plasma concentration and efficacy has been established. The duration of drug effect is presumed to be dependent on the rate of enzyme re-synthesis rather than on the rate of elimination of the drug from the...

Therapeutic areas: Neurology · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VIGAFYDE · VIGABATRIN 100MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vigabatrin" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure938
  • drug ineffective709
  • off label use372
  • hospitalisation315
  • death253
  • adverse event247
  • somnolence197
  • epilepsy191
  • multiple-drug resistance178
  • magnetic resonance imaging head abnormal167
  • drug resistance162
  • vomiting161

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200515
200617
200710
200850
200927
201019
201122
201227
201356
201446
201546
201651
201772
2018236
2019309
2020399
2021439
2022540
2023581
2024685
2025665
2026444

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 261 on PubMed
  • Epilepsy.

    Marson AG, Maguire M, Ramaratnam S · BMJ Clin Evid 2009 · Systematic Review

  • Epilepsy (partial).

    Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2011 · Systematic Review

  • Epilepsy (partial).

    Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2010 · Systematic Review

  • Vigabatrin.

    Reynolds EH · BMJ 1990 · Clinical Trial, Review

  • Vigabatrin.

    Michelucci R, Tassinari CA · Epilepsy Res Suppl 1991 · Clinical Trial, Randomized Controlled Trial

  • Anticonvulsants for cocaine dependence.

    Minozzi S, Cinquini M, Amato L, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't

Sponsor: Pyros Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.